Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02142400
Other study ID # DS1093-A-E102
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 2014
Est. completion date February 2015

Study information

Verified date April 2015
Source Daiichi Sankyo, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomised, double-blind, placebo-controlled multiple ascending single study. It is hypothesised that at least dose of DS-1093a will be safe and tolerable over a 2-week treatment period and will result in increases in reticulocyte count and haemoglobin concentrations in healthy male volunteers


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date February 2015
Est. primary completion date February 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Healthy male subjects, aged 18-45 years.

- A body mass index (BMI, or Quetelet index) in the range 18.0-30.0

- Willing to use a reliable method of contraception during the trial, and for 4 months afterwards

- Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire trial.

- Willingness to give written consent to participate after reading the information and consent form (ICF), and after having the opportunity to discuss the trial with the Investigator or his delegate.

- Willingness to give written consent to have data entered into The Overvolunteering Prevention System.

Exclusion Criteria:

- Clinically relevant abnormal medical history, physical findings, electrocardiogram (ECG), or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.

- Presence of acute or chronic illness or history of chronic illness (particularly hypertension, seizures, kidney disease or liver disease, including known or newly discovered Gilbert's syndrome) sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous.

- Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, or history of psychotic mental illness.

- Presence or history of malignant disease, other than basal cell carcinoma that was successfully treated at least 5 years ago.

- Any medical history that, in the opinion of the Investigator, is suggestive of a significant bleeding or coagulation risk.

- History of venous or arterial thrombosis or embolic disease.

- History of gastric or duodenal ulcer.

- History of treatment with, or use of, an erythropoiesis stimulating agent (e.g. EPO).

- Blood pressure (BP) and heart rate in supine position at the screening examination outside the ranges 90-140 mm Hg systolic, 40-90 mm Hg diastolic; heart rate 40-100 beats/min.

- Haemoglobin concentration of < 129 g/L, platelets outside the normal reference ranges at the screening examination, or evidence of iron deficiency based on serum iron and ferritin levels.

- Surgery (e.g. stomach bypass) or medical condition that might affect absorption of medicines.

- Presence or history of significant hypersensitive or allergic reaction to any drug, except penicillin.

- Use of a prescription medicine or a strong inducer or inhibitor of cytochrome P450 enzymes, during the 30 days before the first dose of trial medication; use of any other over-the-counter medicine, with the exception of acetaminophen (paracetamol), during the 7 days before the first dose of trial medication.

- Participation in another clinical trial of a new chemical entity or a prescription medicine within the previous 3 months, or unwilling to abstain from participating in other clinical trials during the study and for 3 months after receipt of the final dose of trial medication.

- Positive test for hepatitis B, hepatitis C, HIV 1 & HIV 2.

- Abuse of drugs or alcohol during the 2 years before the first dose of trial medication.

- Evidence of drug or alcohol abuse at screening, or intake of more than 21 units of alcohol weekly.

- Use of tobacco or nicotine-containing products during the 3 months before the first dose of trial medication.

- Loss of more than 400 mL blood, or donation of blood, plasma, platelets, or any other blood components, during the 3 months before the trial, or unwilling to abstain from donating during the study and for 3 months after receipt of the final dose of trial medication.

- Possibility that the volunteer will not cooperate with the requirements of the protocol.

- Objection by General Practitioner (GP) to volunteer entering trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
DS-1093
DS-1093 in capsules with 2.5mg or 25mg per capsule
placebo
matching placebo capsules to DS-1093 capsules

Locations

Country Name City State
United Kingdom Hammersmith Medicines Research Ltd London

Sponsors (1)

Lead Sponsor Collaborator
Daiichi Sankyo, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary blood concentration of DS-1093 level of DS-1093 will be determined in participants blood from the time of initial dosing through 15 days after. time of dosing through Day 15
Primary number of adverse events including type and severity number, type and severity of adverse events will be reported during the study from initial randomization through Day 98 date of randomization through Day 98
Secondary levels of EPO Pharmacodynamic (PD) analyses will be conducted for EPO (Erythropoietin ) through 42 days after initial dosing time of dosing through 42 days after dosing
Secondary levels of VEGF Pharmacodynamic (PD) analyses will be conducted forVEGF (Vascular Endothelial Growth Factor) through 42 days of dosing. time of dosing through 42 days after dosing
Secondary levels of H25 Pharmacodynamic (PD) analyses will be conducted for H25 (Hepcidin-25); through 42 days of dosing. time of dosing through 42 days after dosing
Secondary levels of Reticulocytes Pharmacodynamic (PD) analyses will be conducted for hematology markers {RET (Reticulocytes), through 42 days of dosing. time of dosing through 42 days after dosing
Secondary levels of Haemoglobin Pharmacodynamic (PD) analyses will be conducted for hematology markers Hb (haemoglobin), through 42 days of dosing. time of dosing through 42 days after dosing
Secondary levels of Haematocrit Pharmacodynamic (PD) analyses will be conducted for hematology markers HCT (haematocrit), through 42 days of dosing. time of dosing through 42 days after dosing
Secondary levels of Red Blood Cells Pharmacodynamic (PD) analyses will be conducted for hematology marker RBC (red blood cells) through 42 days of dosing. time of dosing through 42 days after dosing
Secondary levels of Serum Iron Pharmacodynamic (PD) analyses will be conducted for iron metabolism marker {SI (Serum Iron) through 42 days of dosing. time of dosing through 42 days after dosing
Secondary levels of Transferrin Pharmacodynamic (PD) analyses will be conducted for iron metabolism markers T (Transferrin), through 42 days of dosing. time of dosing through 42 days after dosing
Secondary levels of TSAT Pharmacodynamic (PD) analyses will be conducted for iron metabolism marker TSAT(Saturated Transferrin) through 42 days of dosing. time of dosing through 42 days after dosing
Secondary levels of Ferrin Pharmacodynamic (PD) analyses will be conducted for iron metabolism marker F (Ferritin) through 42 days of dosing. time of dosing through 42 days after dosing
See also
  Status Clinical Trial Phase
Recruiting NCT05682326 - Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P) Phase 3
Completed NCT03400033 - Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) Phase 3
Completed NCT02879305 - Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) Phase 3
Completed NCT02876835 - Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) Phase 3
Terminated NCT02801162 - Evaluation of Accuracy and Precision of a New Arterial Blood Gas Analysis System Blood in Comparison With the Reference Standard N/A
Completed NCT02288637 - Evaluation of a Novel Long Lasting Insecticidal Net and Indoor Residual Spray Product N/A
Completed NCT00276224 - Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia N/A
Completed NCT00857077 - Intermittent Preventive Treatment for Malaria in Infants in Navrongo Ghana N/A
Completed NCT06080555 - Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia Phase 1
Completed NCT01977573 - A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD) Phase 2
Completed NCT02243306 - Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis Phase 1
Completed NCT01111630 - Study of Erythropoietin (EPO) Administration Schedule Phase 4
Completed NCT00140517 - Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance N/A
Completed NCT03239522 - Absorption and Elimination of Radiolabeled Daprodustat Phase 1
Completed NCT01376232 - Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil) Phase 1
Completed NCT02019719 - Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease Phase 2
Completed NCT02969655 - A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02637102 - The UK CAVIAR Study
Completed NCT01454752 - Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition N/A
Completed NCT01136850 - Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea Phase 3